Livforsakringsbolaget Skandia Omsesidigt Invests $9.71 Million in Halozyme Therapeutics, Inc. $HALO

Posted by Stanley Muller on Aug 29th, 2026

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 124,100 shares of the biopharmaceutical company’s stock, valued at approximately $9,710,000. Livforsakringsbolaget Skandia Omsesidigt owned about 0.11% of Halozyme Therapeutics at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of HALO. Horizon Investment Services LLC purchased a new position in Halozyme Therapeutics during the 2nd quarter worth $2,254,000. Chase Investment Counsel Corp bought a new position in shares of Halozyme Therapeutics during the second quarter valued at about $2,035,000. Mizuho Markets Americas LLC lifted its position in shares of Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock valued at $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Halozyme Therapeutics by 19,326.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after purchasing an additional 85,036 shares during the last quarter. Finally, Aurora Investment Counsel purchased a new position in Halozyme Therapeutics during the second quarter worth about $1,427,000. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $79,987,320.40. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Trading Down 1.5%

Shares of HALO opened at $105.35 on Friday. The business has a 50-day moving average of $87.01 and a 200 day moving average of $74.78. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $109.66. The firm has a market cap of $11.96 billion, a P/E ratio of 31.45, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HALO shares. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. HC Wainwright boosted their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. TD Cowen upped their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Finally, Weiss Ratings cut Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Get Our Latest Report on HALO

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.